Results 301 to 310 of about 126,141 (353)
JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib. [PDF]
Acta Derm VenereolLi Pomi F +4 more
europepmc +1 more source
Infection Risk in Dermatology Patients Receiving Next-Generation Medication: A Meta-Analysis of JAK Inhibitors and Biologics. [PDF]
Medicina (Kaunas)Gupta AK, Susmita, Economopoulos V.
europepmc +1 more source
Real-World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta-Analysis. [PDF]
Clin Exp AllergyKim Y, Seo G, Koopman JJE, Yee J.
europepmc +1 more source
Safety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis. [PDF]
Arthritis Res TherLuozzo LD +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
JAK inhibitors for rheumatoid arthritis
Expert Opinion on Investigational Drugs, 2023JAK (Janus kinase) is a type of non-receptor tyrosine kinase that includes JAK1, JAK2, JAK3, and Tyk2. Currently, there are five JAK inhibitors approved for treating rheumatoid arthritis. These inhibitors vary in their selectivity for different JAK isoforms.This review outlines the mode of actions and the results of Phase III trials of the JAK ...
Satoshi Kubo +2 more
openaire +2 more sources
Future Medicinal Chemistry, 2014
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock +3 more
openaire +2 more sources
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock +3 more
openaire +2 more sources
Current Medicinal Chemistry, 2019
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Musumeci, Francesca +7 more
openaire +3 more sources
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Musumeci, Francesca +7 more
openaire +3 more sources
Drug News & Perspectives, 2005
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire +2 more sources
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2013
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire +1 more source
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire +1 more source